Skip to main content
The Globe and Mail
Get full access to globeandmail.com
Support quality journalism
Just $1.99 per week for the first 24weeks
Just $1.99 per week for the first 24weeks
The Globe and Mail
Support quality journalism
Get full access to globeandmail.com
Globe and Mail website displayed on various devices
Just$1.99
per week
for the first 24weeks

var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){console.log("scroll");var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))}pencilInit(".js-sub-pencil",!1);
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 8.56
Day High 9.16
Open:8.80
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm has CG-806, APTO-253 drugs in preclinical development stage pipeline.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019
- PR Newswire - Tue Dec 10, 7:30AM CST
PR Newswire - CMTX
Tue Dec 10, 7:30AM CST
Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat cancer in all its forms. As the prevalence of cancer rises so does the growth rate of R&D and the resulting increase in revenues. One of the sub-markets of targeted drug oncology to continue to rise is the small molecule oncology market, The National Cancer Institute defines small molecule drugs as: "A substance that is able to enter cells easily because it has a low molecular weight. Once inside the cells, it can affect other molecules, such as proteins, and may cause cancer cells to die. This is different from drugs that have a large molecular weight, such as monoclonal antibodies, which are not able to get inside cells very easily. Many targeted therapies are small-molecule drugs or small molecule inhibitors." Active biotech and pharma companies in the markets this week include CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Clovis Oncology, Inc. (NASDAQ: CLVS), ArQule, Inc. (NASDAQ: ARQL), Aptose Biosciences Inc. (NASDAQ: APTO) (TSX: APS), Fate Therapeutics, Inc. (NASDAQ: FATE).
Aptose to Present at May Investor Conferences
GlobeNewswire - Mon May 13, 7:16AM CDT
GlobeNewswire - CMTX
Mon May 13, 7:16AM CDT
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at two upcoming investor conferences:
Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC
GlobeNewswire - Fri May 10, 6:25PM CDT
GlobeNewswire - CMTX
Fri May 10, 6:25PM CDT
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced, further to its approval by the Toronto Stock Exchange and NASDAQ, the commencement of the $20MM Common Share Purchase Agreement with Aspire Capital Fund, LLC ("Aspire Capital") that was previously announced on May 7, 2019 (the "Agreement"). Aspire Capital has committed to purchase up to $20MM of common shares of Aptose, at Aptose's request from time to time, for up to 30 months. This Agreement replaces the agreement that Aptose entered into with Aspire Capital on May 30, 2018, which has been terminated by the parties. The Agreement limits the amount of Aptose's common shares that Aspire Capital can own at one time to 9.99% of the issued and outstanding common shares of the Company, and limits the maximum number of common shares that can be issued under the Agreement to 19.99% of the Company's outstanding common shares on the date of the Agreement unless shareholder approval is obtained or the shares issued to date once the 19.99% threshold is reached have an average purchase price equal to or exceeding $2.10.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 6.00 +46.50% increase
on 03/16/20
Period Open:9.80
Price movement based on the high, low and last over the given period.
10.59 -17.00% decrease
on 03/10/20
-1.01 (-10.31%) decrease
since 03/09/20
3-Month 6.00 +46.50% increase
on 03/16/20
Period Open:7.80
Price movement based on the high, low and last over the given period.
12.24 -28.19% decrease
on 02/20/20
+0.99 (+12.69%) increase
since 01/09/20
52-Week 2.37 +270.89% increase
on 10/23/19
Period Open:2.55
Price movement based on the high, low and last over the given period.
12.24 -28.19% decrease
on 02/20/20
+6.24 (+244.71%) increase
since 04/09/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies